1. Introduction {#sec1}
===============

Blast-mediated traumatic brain injury (TBI) is a common condition among active and recently-active military personnel, and also affects civilian populations \[[@bib1]\]. Blast-mediated TBI is a traumatic event that needs both acute and chronic management, and symptoms typically manifest and progress chronically \[[@bib2]\]. Identification of individuals with mild TBI or TBI-induced symptoms is difficult for multiple reasons, including self-reporting of blast-exposure. In addition, improvements in protective armor have improved survivability in recent conflicts, which has resulted in an increased incidence of TBI \[[@bib3]\]. Even if TBI is suspected based on the reported history, a confounding factor for symptom-based diagnosis is that individuals with TBI can present with a wide constellation of symptoms which include cognitive, behavioral, neuropsychological, motor and visual impairment \[[@bib4], [@bib5]\]. Many of these symptoms may not be immediately apparent and may only manifest months to years after the initial injury, or are diagnosed post-mortem \[[@bib6], [@bib7]\]. Thus, there is a significant unmet need for objective blood-based biomarkers for mild injuries that can be used to help confirm diagnosis.

A significant challenge to developing tools for diagnosis and therapeutic treatments for blast-mediated mild TBI is that the timing of neuronal loss and the pathways leading to neuronal impairment and degeneration are not well understood. The pathophysiology of blast-mediated TBI is precipitated by the interaction of a blast wave with neuronal tissue. Following this interaction, multiple mechanisms that lead to the death and dysfunction of neurons after exposure to TBI have been reported from several models \[[@bib8], [@bib9], [@bib10]\]. These mechanisms include immediate \[[@bib11], [@bib12], [@bib13]\] and delayed \[[@bib14], [@bib15]\] neuronal changes. In many models, classic markers of apoptotic cell death are not present \[[@bib16]\]. Cellular mechanisms that are believed to lead to neuronal death and dysfunction after mild TBI or repetitive TBI include diffuse axonal injury and myelin damage, excitotoxicity, dysregulation of the neurovascular unit, inflammation, and oxidative stress \[[@bib17], [@bib18], [@bib19], [@bib20], [@bib21]\]. Each of these processes has been individually implicated in contributing to neuronal death; the possibility of their complex combinatorial interactions seems likely, but remains largely untested.

In part because of the difficulties in symptom-based diagnosis and an incomplete knowledge of damage-inducing mechanisms, developing protein-based biomarkers in the body that can serve as a proxy for poorly-accessible organs such as the brain has been a focus of considerable research effort \[[@bib22], [@bib23], [@bib24]\]. Many proteins that are expressed differentially or uniquely during pathogenesis of TBI have been identified. Among the most promising candidates for biomarkers of blast-mediated TBI are several which have proven useful for other forms of acquired brain injury, including: S-100β, neuron specific enolase (NSE), glial fibrillary acid protein (GFAP), myelin basic protein (MBP), and BDNF \[[@bib25]\]. While these proteins have been implicated with varying levels of TBI, their utility in detecting patients with mild blast-mediated TBI has not been completely validated.

Here, we report the discovery of novel candidates for serum-based biomarkers of blast TBI in addition to discovering unique and upregulated proteins in the thalamus in C57BL/6J mice exposed to blast using novel, robust qualitative screens for rapid identification of proteins and analytes of interest. To achieve this, we first identified thalamic proteins differentially or uniquely associated with blast exposure. Next, we identified blast-associated proteins eliciting production of circulating autoantibodies. Finally, results of both approaches were compared to identify the small subset shared in common, i.e. proteins induced by blast that also solicit sustained autoantibody production. We performed these analyses using variations of proteomics-based approaches: proteomics-based analysis of depletomes (PAD) and proteomics-based expression library screening (PELS), which each utilize antibody-based affinity capture of proteins and their characterization using tandem mass spectrometry in different iterations ([Figure 1](#fig1){ref-type="fig"}). The results identify six proteins with properties appropriate for further consideration as biomarkers of blast-mediated TBI, as well as several others previously not known to be associated with blast-injury but potentially relevant to mechanisms of damage caused by blast-exposure. These proteins are: fructose-biphosphate aldolase A, phosphorylase b kinase regulatory subunit beta, alpha globin 1, dihydropyrimidinase-related protein 2, isoform 1b of synapsin 1, and creatine kinase B-type.Figure 1The PELS principle for generation of affinity-captured proteome/depletome used in this study.Figure 1

2. Methods {#sec2}
==========

2.1. Animals {#sec2.1}
------------

All animal studies were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Iowa City Veterans Affairs Institutional Animal Care and Use Committee. The study utilized two experimental groups of mice, which both consisted entirely of male C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME), and were randomly assigned to one of the following treatment groups at 8 weeks of age: 1) mice were exposed to one single blast injury (referred to throughout as "TBI-mice"), or 2) mice were subjected to a sham-injury ("sham-mice"). A total of 92 mice were used in this study.

2.2. Blast injury induction {#sec2.2}
---------------------------

An enclosed blast chamber was used for the purpose of these studies to investigate the effect of primary blast exposure. One half of this tank was pressurized, with a 13-cm opening between the sides of the chamber, as described previously \[[@bib11], [@bib12]\]. A Mylar membrane (Mylar A, 0.00142 gauge; Country Plastics, Ames, IA, USA) was placed over the opening on the pressurized side of the chamber. The unpressurized side of the tank contained a padded polyvinyl chloride (PVC) protective restraint for positioning of an anesthetized mouse 30 cm from the Mylar membrane. Compressed air was pumped into the pressurized side of the tank to 20 psi, at which point the membrane ruptured and created a blast wave. Mice were anesthetized with a combination of ketamine (0.03 mg/g, intraperitoneal \[IP\]) and xylazine (0.005 mg/g, IP) and positioned within the blast chamber with the left side of the head and eye oriented toward the source of the blast wave. To ensure that the primary effect of the blast wave was at the level of the head, only the head of TBI-mice was exposed to the blast wave, with the rest of the body shielded. The head was allowed to move freely and was not fixed in position, although care was taken to ensure that the head did not impact hard surfaces, and was supported from major movement with thick foam placed behind the head. Immediately following exposure to the blast wave, TBI-mice were placed on a heating pad to facilitate recovery from general anesthesia and to prevent hypothermia. Xylazine anesthesia was reversed with yohimbine chloride (0.001 mg/g, IP) to speed the recovery from anesthesia. Control sham-mice used in this study were anesthetized and placed in the blast chamber, but did not receive a blast exposure. TBI-mice and sham-mice equally received analgesic via subcutaneous injection (0.1 mL/20 g body weight) of buprenorphine (0.003 mg/mL) immediately after the blast or sham-blast, respectively.

2.3. Sample collection {#sec2.3}
----------------------

For studies of thalamic proteins, TBI-mice (*n* = 12; 4 weeks post blast) and sham-mice (*n* = 12; 4 weeks post sham injury) were humanely euthanized and thalamic regions micro-dissected. Homogenates from each subject group were pooled together and stored at -80 °C prior to analysis. For studies of circulating auto-antibodies, serum specimens were collected from cardiac punctures of TBI-mice (*n* = 12) and sham-mice (*n* = 12) 8 weeks following blast exposure. Serum specimens were pooled and polyclonal antibodies purified via Protein A affinity chromatography using HiTrap Protein A HP (1 ml) columns (GE Healthcare) per manufacturer guidelines.

2.4. Proteomics-based analysis of depletomes (PAD) {#sec2.4}
--------------------------------------------------

The term "depletome" refers to the complement of interesting molecules resident in a complex mixture, following selective depletion of irrelevant components. To derive the depletome of the thalamus from blast-exposed mice, bait polyclonal antibodies were generated in chickens (IgY) against proteins from pooled thalami of sham-mice (C57BL/6J Male mice, 8 weeks of age at the beginning of the study) using the services of a commercial vendor (Aves Labs, OR), and affinity purified using anti-chicken IgY polyclonal generated in goats. The bait IgY-polyclonal antibodies (titer assessed to be \>1:10,000 in dot immunoblotting against 2 μg of the immunogen mixture) were then covalently coupled to Dynabeads M-280 Tosylactivated (Invitrogen/Life Technologies, CA) and HiTrap NHS-activated columns (1 ml; GE Healthcare Life Sciences) per manufacturer guidelines. The thalamus protein extracts from TBI-mice (complex mixture; 5 mg total protein in 5 mls of PBS \[pH 7.4\]) were reacted first with charged Dynabeads M-280 Tosylactivated and then passed through charged HiTrap NHS-activated columns per manufacturer guidelines. This process of selective depletion of confounding proteins from the complex mixture and the simultaneous enrichment for relevant proteins, resulted in a depletome constituted by proteins that were either differentially (i.e., produced in larger amounts in thalami of TBI-mice than in those of untreated mice, defined as an increase of 1 or more identified peptides compared to untreated mice) or uniquely expressed in thalami of TBI-mice 4 weeks post injury. Increases in protein peptides are commonly used for analysis of high-throughput, qualitative assays of protein expression \[[@bib26]\]. The proteins comprising the depletome were processed and subjected to tandem mass spectrometry for identification. Protein identifications were linked to gene symbols for 75 proteins in the depletome; 2 peptides were excluded (IPI00987580, IPI00224605) because they linked to predicted pseudogenes.

2.5. Proteomics-based expression library screening (PELS) {#sec2.5}
---------------------------------------------------------

The overall strategy followed a published PELS protocol \[[@bib27]\], with variations \[[@bib28]\] to identify host thalamus proteins shed in body fluids following blast-mediated injury. First, "bait" polyclonal antibodies (bait PAbs) were generated from the pooled sera of TBI-mice (8 weeks post blast) and were covalently coupled to HiTrap NHS-activated columns (1 ml; GE Healthcare Life Sciences) creating "charged columns". Next, pooled thalamic protein extracts from TBI-mice (4 weeks post blast) containing the analytes of interest were subjected to immunoaffinity capture by passage through the charged columns. The captured proteins were then eluted and subjected to tandem mass spectrometry for identification. Elutions of the same extracts loaded on NHS columns charged with bait PAbs affinity purified from sera collected from untreated mice and on NHS columns without covalently coupled polyclonal antibodies, but quenched active groups ("uncharged") served as controls for assessing both specificity of bait PAbs and nonspecific adsorption to the column matrix. Protein identifications were linked to gene symbols for 46 proteins identified by PELS; 3 peptides were excluded because they linked to predicted pseudogenes (IPI00987580, IPI00265107) or could not be linked to a gene (IPI00462809).

2.6. Tandem mass spectrometry {#sec2.6}
-----------------------------

Tandem mass spectra were extracted by ABI Analyst version 2.0. All MS/MS samples were analyzed using Mascot (Matrix Science, London, UK; version 2.2.2). Mascot was set up to search the IPI-Mouse FASTA database assuming digestion enzyme trypsin. Protein identifications were accepted if they could be established at greater than 99.0% probability and contained at least two identified unique peptides. Proteins with single peptide hits were included if they exhibited high confidence based on low false discovery rates \[[@bib29]\]. Relative protein abundance was estimated using the normalized total spectral counts \[[@bib30]\]. Protein probabilities were assigned using the Protein Prophet algorithm \[[@bib31]\]. Proteins that contained similar peptides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony.

2.7. Functional annotation and pathway analysis {#sec2.7}
-----------------------------------------------

DAVID \[[@bib32], [@bib33]\] and WebGestalt \[[@bib34], [@bib35]\] were used to compare protein lists against a C57BL/6J mouse brain proteome \[[@bib36]\]. Settings for functional annotation using DAVID utilized the gene symbols for the 75 proteins in the depletome for "gene list" the brain proteome list as "background", and "Mus musculus" as species. Outputs, and their abbreviations used herein, for UP_KEYWORDS (keywords), GOTERM_CC_DIRECT (cellular compartment), GOTERM_MF_DIRECT (molecular function), GOTERM_BP_DIRECT (biological process), KEGG_PATHWAY (KEGG pathway), INTERPRO (protein domains) were compiled into spreadsheets with only terms surpassing statistical significance after multiple hypothesis testing performed by DAVID using the Benjamini-Hochberg method. Settings for WebGestalt utilized the same gene lists described above, with "mmusculus" for species and default settings for all other parameters. One of the 75 genes in the depletome (*Atp5f1b*, IPI00468481) was not recognized by DAVID or WebGestalt because of ortholog ambiguity.

3. Results {#sec3}
==========

To identify thalamic proteins differentially or uniquely associated with blast exposure, we utilized the PAD strategy to identify a depletome of proteins over-represented in the thalamus of TBI-mice at 4 weeks after blast, compared to the thalamus of age-, sex-, and strain-matched sham-mice. This analysis identified 75 proteins ([Table 1](#tbl1){ref-type="table"}). To identify blast-associated proteins eliciting production of circulating autoantibodies, we utilized a variant of the PELS strategy to identify serum antibodies of TBI-mice at 8 weeks post blast that recognize thalamic proteins of TBI-mice at 4 weeks post blast. This analysis identified 46 blast-associated immunogenic proteins ([Table 2](#tbl2){ref-type="table"}). A comparison of the results in common to both approaches, i.e. proteins differentially/uniquely associated with blast exposure *and* those that elicit a sustained production of autoantibodies, identified six proteins ([Table 3](#tbl3){ref-type="table"}).Table 1Depletome proteins identified using PAD.Table 1Identified proteinsAccession numberMolecular weightNumber of unique peptides in thalamus of untreated mouseNumber of unique peptides in depletomeUniProtKBGene SymbolGamma-enolaseIPI0033170447 kDa412[P17183](uniprotkb:P17183){#intref0015}Eno2Serum albuminIPI0013169569 kDa29[P07724](uniprotkb:P07724){#intref0020}AlbCreatine kinase B-typeIPI0013670343 kDa48[Q04447](uniprotkb:Q04447){#intref0025}CkbMalate dehydrogenase, mitochondrialIPI0032359236 kDa17[P08249](uniprotkb:P08249){#intref0030}Mdh2Heat shock cognate 71 kDa proteinIPI0032335771 kDa06[P63017](uniprotkb:P63017){#intref0035}Hspa8Dihydropyrimidinase-related protein 2IPI0011437562 kDa26[O08553](uniprotkb:O08553){#intref0040}Dpysl2Isoform Ib of Synapsin-1IPI00136372 (+1)70 kDa36[O88935](uniprotkb:O88935){#intref0045}Syn114-3-3 protein gammaIPI0023070728 kDa25[P61982](uniprotkb:P61982){#intref0050}YwhagIsoform M2 of Pyruvate kinase isozymes M1/M2IPI00407130 (+1)58 kDa05[P52480](uniprotkb:P52480){#intref0055}PkmAspartate aminotransferase, cytoplasmicIPI0023020446 kDa05[P05201](uniprotkb:P05201){#intref0060}Got1Actin, cytoplasmic 1IPI00110850 (+4)42 kDa24[P60710](uniprotkb:P60710){#intref0065}ActbSuperoxide dismutase \[Cu--Zn\]IPI0013058916 kDa24[P08228](uniprotkb:P08228){#intref0070}Sod1Alpha-enolaseIPI00462072 (+2)47 kDa04[P17182](uniprotkb:P17182){#intref0075}Eno1Tubulin beta-4 chainIPI00109073 (+1)50 kDa04[Q9D6F9](uniprotkb:Q9D6F9){#intref0080}Tubb4aIsoform 1 of Alpha-synucleinIPI00115157 (+1)14 kDa04[O55042](uniprotkb:O55042){#intref0085}SncaTubulin alpha-1A chainIPI00110753 (+3)50 kDa03[P68369](uniprotkb:P68369){#intref0090}Tuba1aStathminIPI0055123617 kDa03[P54227](uniprotkb:P54227){#intref0095}Stmn1Malate dehydrogenase, cytoplasmicIPI0033632437 kDa03[P14152](uniprotkb:P14152){#intref0100}Mdh1Isoform 1 of Microtubule-associated protein 1AIPI00408909 (+1)300 kDa12[Q9QYR6](uniprotkb:Q9QYR6){#intref0105}Map1aTriosephosphate isomeraseIPI00467833 (+1)32 kDa12[P17751](uniprotkb:P17751){#intref0110}Tpi1SH3 domain-binding glutamic acid-rich-like protein 3IPI0012735810 kDa12[Q91VW3](uniprotkb:Q91VW3){#intref0115}Sh3bgrl3Isoform HuC-L of ELAV-like protein 3IPI0012245140 kDa02[Q60900](uniprotkb:Q60900){#intref0120}Elavl3Fructose-bisphosphate aldolase CIPI0011945839 kDa02[P05063](uniprotkb:P05063){#intref0125}Aldoc2-iminobutanoate/2-iminopropanoate deaminaseIPI0013064014 kDa02[P52760](uniprotkb:P52760){#intref0130}RidaPeroxiredoxin-2IPI00117910 (+1)22 kDa02[Q61171](uniprotkb:Q61171){#intref0135}Prdx2Isoform 1 of Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoformIPI00121545 (+2)59 kDa02[P63328](uniprotkb:P63328){#intref0140}Ppp3caAnnexin A5IPI0031730936 kDa02[P48036](uniprotkb:P48036){#intref0145}Anxa5Heat shock protein HSP 90-alphaIPI0033080485 kDa02[P07901](uniprotkb:P07901){#intref0150}Hsp90aa1Elongation factor 1-alpha 2IPI0011966750 kDa02[P62631](uniprotkb:P62631){#intref0155}Eef1a2Isoform Mitochondrial of Peroxiredoxin-5, mitochondrialIPI00129517 (+3)22 kDa02[P99029](uniprotkb:P99029){#intref0160}Prdx5L-lactate dehydrogenase B chainIPI0022951037 kDa02[P16125](uniprotkb:P16125){#intref0165}LdhbRas-related protein Rab-3AIPI0012296525 kDa02[P63011](uniprotkb:P63011){#intref0170}Rab3aUbiquitin carboxyl-terminal hydrolase isozyme L1IPI00313962 (+1)25 kDa02[Q9R0P9](uniprotkb:Q9R0P9){#intref0175}Uchl1Fructose-bisphosphate aldolase AIPI0022140239 kDa02[P05064](uniprotkb:P05064){#intref0180}ALDOAAlpha globin 1IPI0084580215 kDa12[Q91VB8](uniprotkb:Q91VB8){#intref0185}Hba-a1Cytochrome P450, family 2, subfamily c, polypeptide 68IPI00405136 (+1)56 kDa01[Q8VCP4](uniprotkb:Q8VCP4){#intref0190}Cyp2c68Translationally-controlled tumor proteinIPI0012968519 kDa01[P63028](uniprotkb:P63028){#intref0195}Tpt1Proteasomal ubiquitin receptor ADRM1IPI0033115542 kDa01[Q9JKV1](uniprotkb:Q9JKV1){#intref0200}Adrm1Isoform 1 of Serine/threonine-protein kinase SMG1IPI00403352410 kDa01[Q8BKX6](uniprotkb:Q8BKX6){#intref0205}Smg1Isoform 2 of Neurogenic locus notch homolog protein 2IPI00621767243 kDa01[O35516](uniprotkb:O35516){#intref0210}Notch2Isoform 4 of Myocyte-specific enhancer factor 2CIPI00318314 (+1)47 kDa01[Q8CFN5](uniprotkb:Q8CFN5){#intref0215}Mef2cParvalbumin alphaIPI0023076612 kDa01[P32848](uniprotkb:P32848){#intref0220}PvalbNeurograninIPI003802277 kDa01[P60761](uniprotkb:P60761){#intref0225}NrgnPolyadenylate-binding protein 1IPI00124287 (+2)71 kDa01[P29341](uniprotkb:P29341){#intref0230}Pabpc1Histidine triad nucleotide-binding protein 1IPI00108189 (+1)14 kDa01[P70349](uniprotkb:P70349){#intref0235}Hint1Isoform 1 of 60 kDa heat shock protein, mitochondrialIPI00308885 (+1)61 kDa01[P63038](uniprotkb:P63038){#intref0240}Hspd1Isoform 1 of Microtubule-associated protein 6IPI0011583396 kDa01[Q7TSJ2](uniprotkb:Q7TSJ2){#intref0245}Map6Tubulin alpha-4A chainIPI0011735050 kDa01[P68368](uniprotkb:P68368){#intref0250}Tuba4aRas-related protein Rab-1AIPI00114560 (+3)23 kDa01[P62821](uniprotkb:P62821){#intref0255}Rab1aV-type proton ATPase subunit B, brain isoformIPI0011911357 kDa01[P62814](uniprotkb:P62814){#intref0260}Atp6v1b2Protein kinase C and casein kinase substrate in neurons protein 1IPI0012361351 kDa01[Q61644](uniprotkb:Q61644){#intref0265}Pacsin1Isoform IIb of Synapsin-2IPI00134492 (+2)52 kDa01[Q64332](uniprotkb:Q64332){#intref0270}Syn2Isoform 1 of Alpha-adducinIPI00136000 (+4)81 kDa01[Q9QYC0](uniprotkb:Q9QYC0){#intref0275}Add1Profilin-1IPI00224740 (+1)15 kDa01[P62962](uniprotkb:P62962){#intref0280}Pfn1Phosphoglycerate mutase 2IPI00230706 (+1)29 kDa01[O70250](uniprotkb:O70250){#intref0285}Pgam2Rho GDP-dissociation inhibitor 1IPI0032231223 kDa01[Q99PT1](uniprotkb:Q99PT1){#intref0290}ArhgdiaRab GDP dissociation inhibitor alphaIPI0032317951 kDa01[P50396](uniprotkb:P50396){#intref0295}Gdi1Isoform 1 of Structural maintenance of chromosomes protein 5IPI00380203 (+1)129 kDa01[Q8CG46](uniprotkb:Q8CG46){#intref0300}Smc5AmphiphysinIPI0040018075 kDa01[Q7TQF7](uniprotkb:Q7TQF7){#intref0305}AmphATP synthase subunit beta, mitochondrialIPI0046848156 kDa01[P56480](uniprotkb:P56480){#intref0310}Atp5f1bCholine transporter-like protein 3IPI0012228773 kDa01[Q921V7](uniprotkb:Q921V7){#intref0315}Slc44a3Ras-related protein Rab-11BIPI00135869 (+5)24 kDa01[P46638](uniprotkb:P46638){#intref0320}Rab11bUbiquitin-60S ribosomal protein L40IPI00138892 (+11)15 kDa01[P62984](uniprotkb:P62984){#intref0325}Uba52Isoform 3 of NSFL1 cofactor p47IPI00387232 (+2)41 kDa01[Q9CZ44](uniprotkb:Q9CZ44){#intref0330}Nsfl1cMitogen-activated protein kinase 1IPI00119663 (+1)41 kDa01[P63085](uniprotkb:P63085){#intref0335}Mapk1Neurocan core proteinIPI00135563 (+1)137 kDa01[P55066](uniprotkb:P55066){#intref0340}NcanTyrosine-protein phosphatase non-receptor type substrate 1IPI00756790 (+3)17 kDa01[P97797](uniprotkb:P97797){#intref0345}SirpaVomeronasal 2, receptor 112IPI0066071798 kDa01[L7N221](uniprotkb:L7N221){#intref0350}Vmn2r112Adaptin ear-binding coat-associated protein 1IPI0022553330 kDa01[Q9CR95](uniprotkb:Q9CR95){#intref0355}Necap1Transcriptional activator protein Pur-betaIPI0012886734 kDa01[O35295](uniprotkb:O35295){#intref0360}PurbIsoform 1 of D-aminoacyl-tRNA deacylase 1IPI0013371323 kDa01[Q9DD18](uniprotkb:Q9DD18){#intref0365}Dtd1Endophilin-A1IPI00331110 (+3)40 kDa01[Q62420](uniprotkb:Q62420){#intref0370}Sh3gl2Macrophage migration inhibitory factorIPI0023042713 kDa01[P34884](uniprotkb:P34884){#intref0375}Mif14-3-3 protein epsilonIPI00118384 (+1)29 kDa01[P62259](uniprotkb:P62259){#intref0380}YwhaePhosphorylase b kinase regulatory subunit betaIPI00380735124 kDa01[Q7TSH2](uniprotkb:Q7TSH2){#intref0385}PhkbTable 2Identification of proteins shed into circulation after TBI that elicited the formation of autoantibodies in the serum of TBI-mice and identified with PELS.Table 2Identified proteinsAccession numberMolecular weightNumber of unique peptidesUniProtKBGene symbolFructose-bisphosphate aldolase AIPI0022140239 kDa11[P05064](uniprotkb:P05064){#intref0390}ALDOA40S ribosomal protein S19IPI00113241 (+5)16 kDa7[Q9CZX8](uniprotkb:Q9CZX8){#intref0395}Rps19Alpha globin 1IPI0084580215 kDa7[Q91VB8](uniprotkb:Q91VB8){#intref0400}Hba-a140S ribosomal protein S13IPI00125901 (+2)17 kDa6[P62301](uniprotkb:P62301){#intref0405}Rps1360S ribosomal protein L27IPI00122421 (+1)16 kDa6[P61358](uniprotkb:P61358){#intref0410}Rpl27Histone H2B type 1-F/J/LIPI00114642 (+10)14 kDa5[P10853](uniprotkb:P10853){#intref0415}Hist1h2bfHemoglobin subunit beta-1IPI00762198 (+3)16 kDa5[P02088](uniprotkb:P02088){#intref0420}Hbb-b140S ribosomal protein S15IPI00319231 (+1)17 kDa4[P62843](uniprotkb:P62843){#intref0425}Rps15Isoform 2 of 40S ribosomal protein S24IPI00402981 (+4)15 kDa4[P62849](uniprotkb:P62849){#intref0430}Rps2460S ribosomal protein L29IPI00222548 (+9)18 kDa3[P47915](uniprotkb:P47915){#intref0435}Rpl29Histone H1.4IPI0022371422 kDa3[P43274](uniprotkb:P43274){#intref0440}Hist1h1e60S ribosomal protein L13IPI00224505 (+1)24 kDa3[P47963](uniprotkb:P47963){#intref0445}Rpl1360S ribosomal protein L6IPI00313222 (+2)34 kDa3[P47911](uniprotkb:P47911){#intref0450}Rpl640S ribosomal protein S10IPI0011244819 kDa3[P63325](uniprotkb:P63325){#intref0455}Rps1040S ribosomal protein S18IPI00317590 (+2)18 kDa3[P62270](uniprotkb:P62270){#intref0460}Rps1860S ribosomal protein L39IPI00273974 (+4)6 kDa2[P62892](uniprotkb:P62892){#intref0465}Rpl39Isoform 1 of GRB10-interacting GYF protein 2IPI00473912 (+1)149 kDa2[Q6Y7W8](uniprotkb:Q6Y7W8){#intref0470}Gigyf240S ribosomal protein S7IPI00136984 (+1)22 kDa2[P62082](uniprotkb:P62082){#intref0475}Rps740S ribosomal protein S29IPI002225537 kDa2[P62274](uniprotkb:P62274){#intref0480}Rps2960S ribosomal protein L35aIPI00115902 (+1)13 kDa2[O55142](uniprotkb:O55142){#intref0485}Rpl35aHistone H2A.JIPI00153400 (+13)14 kDa2[Q8R1M2](uniprotkb:Q8R1M2){#intref0490}H2afjIsoform Ib of Synapsin-1IPI00136372 (+1)70 kDa2[O88935](uniprotkb:O88935){#intref0495}Syn1Isoform 2 of Heterogeneous nuclear ribonucleoprotein QIPI00406118 (+3)63 kDa1[Q7TMK9](uniprotkb:Q7TMK9){#intref0500}SyncripIsoform 2 of Calcium-activated potassium channel subunit alpha-1IPI00120643 (+12)135 kDa1[Q08460](uniprotkb:Q08460){#intref0505}Kcnma160S ribosomal protein L18IPI00555113 (+1)22 kDa1[P35980](uniprotkb:P35980){#intref0510}Rpl18CCAAT/enhancer-binding protein betaIPI00116613 (+3)31 kDa1[P28033](uniprotkb:P28033){#intref0515}Cebpb60S ribosomal protein L8IPI0013778728 kDa1[P62918](uniprotkb:P62918){#intref0520}Rpl860S ribosomal protein L35IPI00263879 (+1)15 kDa1[Q6ZWV7](uniprotkb:Q6ZWV7){#intref0525}Rpl35Histone H1.3IPI0033159722 kDa1[P43277](uniprotkb:P43277){#intref0530}Hist1h1dAnti-colorectal carcinoma light chainIPI00462809 (+7)26 kDa1[Q7TS98](uniprotkb:Q7TS98){#intref0535}N/AIsoform 1 of Protein FAM126BIPI00226426 (+1)59 kDa1[Q8C729](uniprotkb:Q8C729){#intref0540}Fam126bV-type proton ATPase subunit G 2IPI00123817 (+1)14 kDa1[Q9WTT4](uniprotkb:Q9WTT4){#intref0545}Atp6v1g2Plexin-A2IPI00137313212 kDa1[P70207](uniprotkb:P70207){#intref0550}Plxna2Nuclear receptor subfamily 1 group D member 2IPI0011917864 kDa1[Q60674](uniprotkb:Q60674){#intref0555}Nr1d2Serine/arginine-rich splicing factor 2IPI00121135 (+2)25 kDa1[Q62093](uniprotkb:Q62093){#intref0560}Sfrs2Keratin, type II cytoskeletal 6BIPI00131366 (+7)60 kDa1[Q9Z331](uniprotkb:Q9Z331){#intref0565}Krt6bIsoform 1 of Dynamin-1IPI00272878 (+5)98 kDa1[P39053](uniprotkb:P39053){#intref0570}Dnm160S ribosomal protein L24IPI00323806 (+3)18 kDa1[Q8BP67](uniprotkb:Q8BP67){#intref0575}Rpl24Isoform 1 of Syntaxin-binding protein 1IPI00415402 (+2)68 kDa1[O08599](uniprotkb:O08599){#intref0580}Stxbp1Peptidyl-prolyl cis-trans isomerase AIPI0055498918 kDa1[P17742](uniprotkb:P17742){#intref0585}PpiaProbable G-protein coupled receptor 158IPI00465871134 kDa1[Q8C419](uniprotkb:Q8C419){#intref0590}Gpr158Succinyl-CoA ligase \[GDP-forming\] subunit alpha, mitochondrialIPI00406442 (+1)36 kDa1[Q9WUM5](uniprotkb:Q9WUM5){#intref0595}Suclg1LYR motif-containing protein 4IPI0016980411 kDa1[Q8K215](uniprotkb:Q8K215){#intref0600}Lyrm4Phosphorylase b kinase regulatory subunit betaIPI00380735124 kDa1[Q7TSH2](uniprotkb:Q7TSH2){#intref0605}PhkbDihydropyrimidinase-related protein 2IPI0011437562 kDa1[O08553](uniprotkb:O08553){#intref0610}Dpysl2Creatine kinase B-typeIPI0013670343 kDa1[Q04447](uniprotkb:Q04447){#intref0615}CkbTable 3Potential TBI biomarkers simultaneously identified with PELS and PAD.Table 3Identified proteinsAccession numberMolecular weightNumber of unique peptides in thalamus of untreated mouseNumber of unique peptides in depletomeNumber of unique peptides identified as immunogenic with PELSUniProtKBGene symbolFructose-bisphosphate aldolase AIPI0022140239 kDa0211[P05064](uniprotkb:P05064){#intref0620}ALDOAPhosphorylase b kinase regulatory subunit betaIPI00380735124 kDa011[Q7TSH2](uniprotkb:Q7TSH2){#intref0625}PhkbAlpha globin 1IPI0084580215 kDa127[Q91VB8](uniprotkb:Q91VB8){#intref0630}Hba-a1Dihydropyrimidinase-related protein 2IPI0011437562 kDa261[O08553](uniprotkb:O08553){#intref0635}Dpysl2Isoform Ib of Synapsin-1IPI00136372 (+1)70 kDa362[O88935](uniprotkb:O88935){#intref0640}Syn1Creatine kinase B-typeIPI0013670343 kDa481[Q04447](uniprotkb:Q04447){#intref0645}Ckb

To test whether these protein lists included an over-representation of any gene ontology terms, the DAVID ([Table 4](#tbl4){ref-type="table"}) and WebGestalt ([Table 5](#tbl5){ref-type="table"}) databases were utilized to compare our results to a previously published C57BL/6J mouse brain proteome \[[@bib36]\]. Analysis of the PAD-identified depletome indicated a wide-range of over-represented ontology terms. From analysis with DAVID, the most statistically significant over-represented terms of the depletome were both in the "Cellular Component" category, "Myelin sheath" (27 members, *P* = 3.7E-24) and "Extracellular exosome" (41 members, *P* = 1.7E-10). From analysis with WebGestalt, the statistical significance levels were less pronounced and more closely clustered, with several of the top terms in the "Cellular Component" category involving synapse- or axon-related ontology terms (including, "Neuron projection, 17 members, *P* = 2.09E-5; and "Axon", 9 members, *P* = 6.0E-4).Table 4Gene ontology term and pathway analysis using the DAVID database.Table 4Depleteome (74)Keywords:Acetylation (37) 1.3E-4Phosphoprotein (52) 1.9E-4Glycolysis (6) 1.0E-4Cytoplasm (35) 1.0E-3Nitration (5) 7.8E-3Methylation (14) 3.3E-2Biological Process:Glycolytic process (6) 6.8E-4Cellular Component:Myelin sheath (27) 3.7E-24Extracellular exosome (41) 1.7E-10Cytosol (28) 5.6E-6Cytoplasm (46) 4.9E-4Extracellular space (16) 9.0E-5Axon (11) 6.3E-4Terminal bouton (9) 9.5E-6Synaptic vesicle (8) 5.7E-4Neuron projection (10) 1.6E-2Neuronal cell body (11) 1.5E-2Axon terminus (5) 1.6E-2Protein complex (12) 3.3E-3Blood microparticle (5) 1.7E-2Molecular Function:MHC Class II protein complex binding (4) 2.1E-2Catalytic activity (12) 1.5E-2KEGG Pathway:Carbon metabolism (9) 2.3E-3Glycolysis/Gluconeogenesis (7) 2.3E-3Biosynthesis of antibiotics (10) 6.1E-3Biosynthesis of amino acids (7) 4.6E-3Table 5Gene ontology term and pathway analysis using the WebGestalt database.Table 5Depleteome (74)Biological Process:Multicellular organismal process (32) 1.0E-4Catabolic process (22) 4.0E-4Single-multicellular organism process (32) 1.0E-4Organonitrogen combound metabolic process (20) 5.0E-4Nucleobase-containing small molecular metabolic process (16) 3.0E-4Monosaccharide catabolic process (6) 3.0E-4Hexose catabolic process (6) 3.0E-4Generation of precursor metabolites and energy (10) 4.0E-1Glucose catabolic process (6) 3.0E-4Glycolysis (6) 1.0E-4Cellular Component:Synapse (13) 1.0E-4Synapse part (10) 6.0E-4Cell projection (21) 1.8E-5Neuron projection (17) 2.09E-5Axon (9) 6.0E-4Cytoplasm (51) 2.45E-5Cytosol (22) 9.56E-8Coated vesicle (9) 3.32E-5Clathrin-coated vesicle (7) 6.0E-4Synaptic vesicle (6) 7.0E-4Molecular Function:Binding (50) 4.9E-3Catalytic activity (36) 2.6E-3Cell surface binding (4) 8.0E-4Protein binding (40) 1.1E-3Enzyme binding (15) 2.6E-3Phosphoprotein binding (4) 5.8E-3Protein phosphorylated amino acid binding (3) 4.9E-3Malate dehydrogenase activity (2) 9.1E-0.03Phosphopyruvate hydratase activity (2) 4.9 E-3L-malate dehydrogenase activity (2) 2.6E-3KEGG Pathway:Glycolysis/Gluconeogenesis (6) 4.0E-4Pyruvate metabolism (4) 1.5E-2Neurotrophin signaling pathway (4) 4.9E-2Phagosome (4) 4.9E-2Oocyte meiosis (4) 4.9E-2Phenylalanine metabolism (2) 4.9E-2

The cognitive function of mice was tested with the Morris water maze, a measure of hippocampal dependent learning and memory, in order to demonstrate that bTBI was inducing damage in the brain. Our results demonstrate that blast exposure did not affect learning during the training period of the task ([Supplemental Figure 1](#appsec1){ref-type="sec"}A), but did result in a significant decrease in memory retention in mice with TBI compared to sham-blast mice ([Supplemental Figure 1](#appsec1){ref-type="sec"}B, *P* = 0.0021). The average speed of each mouse calculated during the probe-test was not significantly different between sham and TBI-mice ([Supplemental Figure 1](#appsec1){ref-type="sec"}C). The range of distributions for each parameter demonstrated that TBI induction results in consistent phenotypes without significant outliers. Anti-GFAP staining was performed in the brain to evaluate the astrocytic response to blast exposure ([Supplemental Figure 2](#appsec1){ref-type="sec"}). These results demonstrate that there is not significant GFAP reactivity in the brains of mice 4 weeks following blast exposure when compared to sham-mice. These results also demonstrate that the intra-animal response to blast is uniform.

4. Discussion {#sec4}
=============

We have utilized novel proteomics-based qualitative approaches to identify candidates for serum-based biomarkers of TBI. We focused our study on the thalamus, as it is a major sensory relay station in the brain, and previous findings of both auditory and visual difficulties have been observed in humans following blast-mediated TBI \[[@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43], [@bib44]\]. Thus, the thalamus may be a site particularly prone to damage and appropriate for developing biomarkers. Using a previously described mouse model for studying blast-induced mild TBI, our current analysis identified six proteins with properties appropriate for further consideration as biomarkers of blast-mediated TBI, as well as several others previously not known to be associated with blast-injury and which may be relevant to ongoing mechanistic studies of damage caused by blast-exposure.

If developed, biomarkers could be of particular use with patients in which overt traumatic blast injuries were not sustained, but mild or chronic TBI is suspected. The identification and routine use of biomarkers could help to particularly improve the quality of life of Warfighters and Veterans, for whom mild to moderate cases of TBI might otherwise go undiagnosed. Many Veterans who have been exposed to blast complain of sensory impairment chronically post injury, but lack clearly identifiable diagnoses. For example, many blast-exposed Veterans complain of vision problems, have no measurable deficits in the visual pathway, but none-the-less progress to develop chronic visual impairments. Biomarkers could lead to the earlier identification of such patients and also promote their better monitoring and possible treatment.

A history of exposure to a blast from an explosion is common among Veterans of recent military conflicts. Blast exposures account for nearly 75% of combat-related injuries -- 50% of which result in a diagnosis of mild TBI \[[@bib45], [@bib46]\]. Blast exposure results in axonal damage in the brain \[[@bib47]\], and individuals exposed to blast often report chronic dysfunction of sensory organs \[[@bib48]\]. Sensory system dysfunction in humans increases with repetitive blast exposure \[[@bib49]\], and is reported in greater numbers further from the time of injury \[[@bib50]\]. Damage to the visual system is found in both humans and preclinical models exposed to blast \[[@bib51]\], although the mechanism of injury has not been elucidated \[[@bib37]\]. Damage to the visual system has been reported in a variety of rodent bTBI models \[[@bib11], [@bib52], [@bib53]\], which replicates visual dysfunction observed in Veterans exposed to blast \[[@bib54], [@bib55]\]. Visual dysfunction can be observed immediately following injury \[[@bib56]\], with deficits persisting months after the injury \[[@bib57]\]. The visual system damage observed after blast exposure is similar to damage observed in weight drop models of TBI \[[@bib52], [@bib58], [@bib59]\], suggesting similar mechanisms. These mechanisms are varied and include axonal damage, activation of microglia, tissue swelling, infiltration of immune cells, upregulation of chemoattractants, and neuroinflammation \[[@bib8], [@bib60], [@bib61], [@bib62], [@bib63], [@bib64], [@bib65], [@bib66], [@bib67]\].

The current study was designed based on using damage to the eye as a surrogate for sensory impairment in general, as sensory impairment, particularly visual function, is diminished by blast and non-blast TBI exposure \[[@bib41], [@bib68]\]. Thus, we sought to identify protein changes at a time point after blast exposure (4 weeks) when visual function has a transient recovery from deficits observed 1 h to one week following bTBI \[[@bib11]\], but subtle physiologic abnormalities to visual stimuli can none-the-less be detected \[[@bib12]\]. The visual function in this model declines significantly below baseline by two months post injury, and remains suppressed until at least 10 months post bTBI \[[@bib11]\]. Although these time frames might all be considered "acute" for humans, in the context of the comparatively shortened life-span of a mouse, it is reasonable to surmise that they may roughly correlate to the pertinent time frame for a human who has been exposed to blast, sustained a mild TBI injury, and is manifesting an early stage of chronic sensory pathology when additional diagnosis tools could be useful.

Among the autoantibodies that were detected, there were identifiable links with other diseases and damage to CNS tissues. Notably, a recent study of autoantibodies that increase at the subacute phase of human spinal cord injury \[[@bib69]\] discovered elevated levels of autoantibodies of three proteins also identified by our analyses: alpha globin alpha (HBA-A1), alpha globin beta (HBA-B1), and peptidyl-prolyl cis-trans isomerase A (PPIA). Amongst these, HBA-A1 stands out because it was identified by both our depletome and PELS analyses. As well as functioning in red blood cells, HBA and HBB have also been detected in brain neurons and hypothesized to have a role in response to injury \[[@bib70]\]. PPIA, also referred to as cyclophilin A, is the intracellular receptor for the immunosuppressant cyclosporin A, and functions physiologically as a chaperone or foldase \[[@bib71]\]. Though speculative, Arevalo-Martin *et al.* have previously hypothesized that autoantibodies to PPIA may promote immunosenescence after spinal cord injury \[[@bib69]\]. Our results also included a large signature for antibodies directed against ribosomal proteins. Although autoantibodies to three ribosomal proteins (commonly referred to as P0, P1, and P2; encoded by *RPLP0*, *RPLP1*, and *RPLP2*, respectively) have previously been associated with systemic lupus erythematosus \[[@bib72]\], autoantibodies to these specific ribosomal proteins were not detected in our analysis. Also of relevance, our analysis did not detect autoantibodies to myelin-associated proteins such as myelin oligodendrocyte glycoprotein (MOG) or myelin basic protein (MBP) which are hallmarks of multiple sclerosis \[[@bib73]\].

Our findings also have implications with respect to mechanisms of blast-mediated injury. In our analysis of the thalamic depletome, the most pronounced pathway perturbation was clearly to proteins with links to the myelin sheath. Perturbations involving myelin have previously been observed in differing mouse models of blast-induced TBI \[[@bib74], [@bib75], [@bib76]\]. In this regard, the common identification of this pathway hints that although each of these models evokes blast damage in differing ways, that there are none-the-less similarities in some of the basic mechanisms of injury. As reviewed by Fehily and Fitzgerald \[[@bib10]\], demyelination or dysmyelination can involve multiple mechanisms, including sensitivity of oligodendrocytes, oligodendrocyte progenitor cells, glutamate excitotoxicity, calcium overload, oxidative stress, and/or altered metabolism, among others.

A second pathway with potential mechanistic relevance, which was specifically identified by WebGestalt, was "L-malate dehydrogenase activity" (2 members, *P* = 2.6E-3). The malate-aspartate shuttle is a biochemical reaction pathway that is important in regenerating NADH from NAD(+) within the mitochondrial matrix \[[@bib77]\]. It has previously been shown that disruption of the NAD(+) pathway results in mitochondrial damage and neuronal death. Analysis of models of moderate brain injury has shown presence of chronic mitochondrial dysfunction and reduced antioxidant activity \[[@bib78]\], and that lack of efficient re-synthesis of NAD(+) controlled by NAMPT leads to tissue damage in ischemic tissue \[[@bib78], [@bib79]\]. We, and others, have previously shown that treatment with a neuroprotective compound that increases NAD salvage via NAMPT \[[@bib80]\] reduces the severity of neuronal damage in blast-exposed mice \[[@bib12], [@bib13]\] and mice with fluid-percussion injury \[[@bib81], [@bib82]\].

Some proteins identified in our study were previously identified as upregulated in a proteomic analysis of optic nerves from mice subjected to repetitive blunt impact TBI \[[@bib59]\]. These proteins included ALB, MAP1A, and TUBA4A. A down-regulation of DPYSL2 was observed following repetitive impact TBI in the optic nerve. While we did not observe a change in DPYSL2 in the thalamus, we did detect auto-antibodies to DPYSL2 in the serum. These models also shared increases in similar classes of proteins, including peroxiredoxins, heat shock proteins and ATPases. Taken together these data suggest that similar molecular mechanisms are responsible for cell death and dysfunction in blast and blunt-trauma mediated TBI.

Our current study had caveats that are important to note. Regarding the injury, it is relevant that brain injury comes in many forms and intensities. Our study focused on mild blast-mediated TBI, which will have a very different presentation and protein profile than moderate to severe TBIs, or penetrating and concussive-mediated TBIs. The mild nature of our injury may explain why classic markers of TBI such as GFAP, UCH-L1 and S-100β were not detected. We have characterized many of the physical features of our blast protocol (including a pressure/time profile, overpressure, positive phase and duration) \[[@bib83]\], which will help the comparison of these studies to other models of blast-mediated and non-blast mediated TBI. It should be noted that the visual and cognitive dysfunction we have previously reported using our model \[[@bib11], [@bib12], [@bib13], [@bib84]\] is bilateral, suggesting a lack of effect from blunt impacts, and these same dysfunctions are frequently observed in Soldiers and Veterans exposed to blast injury \[[@bib37], [@bib38], [@bib42], [@bib43], [@bib85], [@bib86]\]. This study also only focused on a single brain region, whereas past studies have focused globally on the brain or brain-connected fluids \[[@bib23]\]. While this does not limit the impact of our study in beginning to define the molecular events that lead to sensory damage after blast-mediated TBI, we do not know if other regions of the brain, or other CNS neurons, respond similarly to blast injury. Our study, performed at a single time point following injury, is also only a "snapshot" of the changes in brain proteins and it does not address how protein expression changes over time. Completion of additional replicates, whether by PELS or by other technologies, will be an important component of future work, in addition to analysis of expression change over time.

Regarding the modeling with mice, our study was conducted in a single strain and sex of mice. We selected the strain (C57BL/6J) because it represents the most widely utilized genetic background of mice. However, our choice of species, genetic background, and sex could all bias the results, and it will be important to extend future studies to females and also different strains and species. Also of relevance, the brain tissue and sera were pooled to analyze proteins that change after blast injury. While it is important to examine the expression profiles of these proteins and auto-antibodies in individual mice, it was beyond the current scope to perform replication studies of candidates within individual mice to assess individual variability of the findings. It should be noted that the method of inducing blast-mediated TBI that was used in this study results in uniform damage among mice exposed to blast. Previously published transcriptomic studies using this model demonstrates very little intra-animal variability in gene expression changes \[[@bib87]\].

Finally, regarding our proteomic methodology, it is important to re-iterate that we only sought to identify proteins with increased abundance in response to blast. We did not attempt to identify proteins that might have decreased abundance in response to blast. As with all protein studies, there is the possibility that protein-protein interactions may exist, although we believe that the likelihood of this happening in this study is low, given the high confidence of the identification methods used, the fact that proteins identified in certain fractions were expected, and the fact that our fractionation and differentiation approaches are widely used and designed to reduce this possibility.

In summary, a combined PAD and PELS analysis identified six proteins with properties appropriate for further consideration as biomarkers of blast-mediated TBI (ALDOA, PHKB, HBA-A1, DPYSL2, SYN1, and CKB), as well as several others potentially relevant to the incompletely understood mechanisms of damage caused by blast-exposure. In our opinion, HBA-A1 stands out as a leading candidate for further testing as a biomarker, and cellular responses involving myelin seem likely to be of mechanistic importance, both of which we intend to test in our ongoing work.
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